McAndrews, Held & Malloy


	Thomas J. Campbell Jr. Associate Email. tcampbell@mcandrews-ip.com Tel. (312) 775-8000 Practice Areas Intellectual Property Education University of Notre Dame, B.S., Biochemistry, 2002 DePaul University College of Law, J.D., cum laude, 2009 Bar Admissions Admitted to practice in Illinois. Professional Experience Thomas joined McAndrews, Held & Malloy as a law clerk in 2008 and became a full time associate in 2010. Since joining the firm, Thomas has gained experience in patent, trademark, copyright, and trade secret litigation covering a variety of technological and business areas. Thomas also has experience in trademark and patent prosecution. As a clerk, he played an integral role in securing a victory for a client before the International Trade Commission. During and prior to law school, Thomas worked for Abbott Laboratories as a pharmacologist. Thomas worked within the Advanced Technology Division to identify potential drug candidates and generated a cardiovascular side-effect profile for selected drug candidates. His skill as a researcher was recognized in 2005 when he received Abbott’s Global Pharmaceutical Research and Development Award for Leadership. As a law student, Thomas excelled in intellectual property law courses such as International Intellectual Property, Patent Law, Advanced Intellectual Property Topics and Biotechnology Patent Strategies. Based on his coursework, Thomas earned a Certificate in Patent Law. He also gained practical experience while advising pro bono clients at the DePaul Technology/Intellectual Property Clinic. Thomas is a trained mediator and has been certified by the Center for Conflict Resolution in Chicago. He has conducted numerous mediations in Illinois state court while attending law school. As an undergraduate student, Thomas conducted various chemical and biological research both at the University of Notre Dame and University of Chicago. Thomas’s chemical research was directed toward organometallic catalysis. His biological research involved investigating the underlying causes of diabetes – including the molecular biology of ion channels and the role genetics played in beta cell dysfunction. Publications Co-author, “The end may be near for reverse payment settlements.” National Law Journal, Oct. 12, 2009. Co-author, “Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs.” Journal of Cardiovascular Pharmacology, December, 2009. Co-author, “Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.” American Journal of Physiology - Heart and Circulatory Physiology, January, 2008. Co-author, “Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.” Journal of Medicinal Chemistry, June, 2007. Co-author, “Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.” Journal of Medicinal Chemistry, November, 2006. Co-author, “Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.” Journal of Medicinal Chemistry, April, 2006. Co-author, “Postischemic administration of CGX-1051, a peptide from cone snail venom, reduces infarct size in both rat and dog models of myocardial ischemia and reperfusion.” Journal of Cardiovascular Pharmacology, August, 2005. Back to Top